{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:08:14Z","timestamp":1789884494154,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ejca.2019.03.023","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T18:54:52Z","timestamp":1558119292000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-9826","authenticated-orcid":false,"given":"Lars","family":"Bastholt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1088-7242","authenticated-orcid":false,"given":"Jon Kroll","family":"Bjerregaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asbj\u00f8rn","family":"Hr\u00f3bjartsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.03.023_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.bjc.6602702","article-title":"Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model","volume":"93","author":"Schmidt","year":"2005","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2019.03.023_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/1097-0142(19930715)72:2<607::AID-CNCR2820720245>3.0.CO;2-R","article-title":"Interferon-alfa and interleukin-2 in the treatment of metastatic melanoma","volume":"72","author":"Keilholz","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.03.023_bib3","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2006.09.0274","article-title":"Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American joint committee on cancer stage IV melanoma: results of the EORTC 18951 biochemotherapy trial","volume":"25","author":"Schmidt","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.03.023_bib4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/1097-0142(19930715)72:2<607::AID-CNCR2820720245>3.0.CO;2-R","article-title":"Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials","volume":"72","author":"Keilholz","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.03.023_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2019.03.023_bib6","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant Interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2019.03.023_bib7","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update","volume":"6","author":"Atkins","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.ejca.2019.03.023_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.1999.17.2.651","article-title":"Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma","volume":"17","author":"Richards","year":"1999","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2019.03.023_bib9","first-page":"S99","article-title":"The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program","volume":"6","author":"Keilholz","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.ejca.2019.03.023_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147153","article-title":"Annual hospital volume of high dose interleukin-2 and inpatient mortality in melanoma and renal cell carcinoma patients","volume":"11","author":"Mehta","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2019.03.023_bib11","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1200\/JCO.1997.15.7.2579","article-title":"Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the european organization for research and treatment of cancer melanoma cooperative group","volume":"15","author":"Keilholz","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.03.023_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/CJI.0000000000000149","article-title":"Clinical response rates from interleukin-2 therapy for metastatic melanoma over 30 Years' experience: a meta-analysis of 3312 patients","volume":"40","author":"Bright","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2019.03.023_bib13","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1060::AID-CNCR8>3.0.CO;2-2","article-title":"Randomized trial of treatment with cisplatin\u00a0and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study","volume":"85","author":"Dorval","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.03.023_bib14","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/S0959-8049(02)00123-5","volume":"38","author":"Keilholz","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.03.023_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2051-1426-2-13","article-title":"Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program","volume":"2","author":"Payne","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2019.03.023_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/CJI.0b013e3182742c27","article-title":"Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2","volume":"35","author":"Joseph","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2019.03.023_bib17","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.03.023_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40425-016-0155-8","article-title":"A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma","volume":"4","author":"Buchbinder","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2019.03.023_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2019.03.023_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179431","article-title":"Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy","volume":"12","author":"Charych","year":"2017","journal-title":"PLoS One"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T18:44:44Z","timestamp":1565117084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919302357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":20,"alternative-id":["S0959804919302357"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.03.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}